and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.cortisoneMonitor Closely (1)cortisone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.crizotinibMonitor Closely (1)crizotinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.cyclizineMonitor Closely (1)cyclizine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprineMonitor Closely (2)cyclobenzaprine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias cyclobenzaprine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.darifenacinMonitor Closely (1)darifenacin and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.dasatinibMonitor Closely (1)dasatinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdegarelixMonitor Closely (1)degarelix and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdesipramineMonitor Closely (2)desipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias tiotropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.deutetrabenazineMonitor Closely (1)deutetrabenazine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexamethasoneMonitor Closely (1)dexamethasone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.dichlorphenamideMonitor Closely (1)dichlorphenamide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.dicyclomineMonitor Closely (1)dicyclomine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.dimenhydrinateMinor (1)dimenhydrinate increases toxicity of tiotropium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.diphenhydramineMonitor Closely (1)diphenhydramine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.disopyramideMonitor Closely (1)disopyramide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdobutamineMonitor Closely (1)dobutamine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsdofetilideMonitor Closely (1)dofetilide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdolasetronMonitor Closely (1)dolasetron and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdonepezilMonitor Closely (2)donepezil and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. donepezil increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)donepezil decreases effects of tiotropium by pharmacodynamic antagonism. Minor/Significance Unknown.donepezil transdermalMonitor Closely (1)donepezil transdermal, tiotropium. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopamineMonitor Closely (1)dopamine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsdosulepinMonitor Closely (1)tiotropium and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinMonitor Closely (2)tiotropium and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor. doxepin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdronedaroneMonitor Closely (1)dronedarone and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasdroperidolMonitor Closely (4)tiotropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. tiotropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. droperidol increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. droperidol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasechothiophate iodideMonitor Closely (1)echothiophate iodide increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzMonitor Closely (1)efavirenz and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.encorafenibMonitor Closely (1)encorafenib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.entrectinibMonitor Closely (1)entrectinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.ephedrineMonitor Closely (1)ephedrine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsepinephrineMonitor Closely (1)epinephrine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsepinephrine racemicMonitor Closely (1)epinephrine racemic and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectseribulinMonitor Closely (1)eribulin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.erythromycin baseMonitor Closely (1)erythromycin base and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiaserythromycin ethylsuccinateMonitor Closely (1)erythromycin ethylsuccinate and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiaserythromycin lactobionateMonitor Closely (1)erythromycin lactobionate and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiaserythromycin stearateMonitor Closely (1)erythromycin stearate and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasescitalopramMonitor Closely (1)escitalopram and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasethacrynic acidMonitor Closely (1)ethacrynic acid and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.fesoterodineMonitor Closely (1)fesoterodine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.fexinidazoleSerious - Use Alternative (1)fexinidazole and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.fingolimodMonitor Closely (1)fingolimod and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.flavoxateMonitor Closely (1)flavoxate and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainideMonitor Closely (1)flecainide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasfluconazoleMonitor Closely (1)fluconazole and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasfludrocortisoneMonitor Closely (1)fludrocortisone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.fluoxetineMonitor Closely (1)fluoxetine and olodaterol inhaled both increase QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular systemfluphenazineMonitor Closely (4)fluphenazine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias fluphenazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. tiotropium decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. tiotropium decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.formoterolMonitor Closely (1)formoterol and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effectsfoscarnetMonitor Closely (1)foscarnet and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasfostemsavirMonitor Closely (1)olodaterol inhaled and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. furosemideMonitor Closely (1)furosemide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.galantamineMonitor Closely (1)galantamine increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)galantamine decreases effects of tiotropium by pharmacodynamic antagonism. Minor/Significance Unknown.gemifloxacinMonitor Closely (1)gemifloxacin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasgilteritinibMonitor Closely (1)gilteritinib and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.glucagonSerious - Use Alternative (1)glucagon increases toxicity of tiotropium by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .glucagon intranasalSerious - Use Alternative (1)glucagon intranasal increases toxicity of tiotropium by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .glycopyrrolateMonitor Closely (1)glycopyrrolate and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledMonitor Closely (1)glycopyrrolate inhaled and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, tiotropium. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.haloperidolMonitor Closely (4)haloperidol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias tiotropium decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. tiotropium decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. haloperidol increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hawthornMonitor Closely (1)hawthorn and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiashenbaneMonitor Closely (1)henbane and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropineMonitor Closely (1)homatropine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrochlorothiazideMonitor Closely (1)hydrochlorothiazide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.hydrocortisoneMonitor Closely (1)hydrocortisone and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.hyoscyamineMonitor Closely (1)hyoscyamine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)hyoscyamine spray and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.ibutilideMonitor Closely (1)ibutilide and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasiloperidoneMonitor Closely (4)tiotropium decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. tiotropium decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. iloperidone increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. iloperidone and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasimipramineMonitor Closely (2)tiotropium and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. imipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasindacaterol, inhaledMonitor Closely (1)indacaterol, inhaled and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route